A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
NCT ID: NCT02935634
Last Updated: 2023-06-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
190 participants
INTERVENTIONAL
2016-11-29
2022-05-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.
NCT03784040
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
NCT02999295
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NCT03704077
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
NCT03776487
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
NCT03443856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nivolumab + Ipilimumab
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Nivolumab + Relatlimab
Nivolumab
Specified dose on specified days
Relatlimab
Specified dose on specified days
Nivolumab + BMS-986205
Nivolumab
Specified dose on specified days
BMS-986205
Specified dose on specified days
Nivolumab + Rucaparib
Nivolumab
Specified dose on specified days
Rucaparib
Specified dose on specified days
Ipilimumab + Rucaparib
Ipilimumab
Specified dose on specified days
Rucaparib
Specified dose on specified days
Nivolumab + Ipilimumab + Rucaparib
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Rucaparib
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Relatlimab
Specified dose on specified days
BMS-986205
Specified dose on specified days
Rucaparib
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
* At least 1 lesion with measurable disease
Exclusion Criteria
* Suspected, known or progressive central nervous system metastases
* Other active malignancy requiring concurrent intervention
* Active, known or suspected autoimmune disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clovis Oncology, Inc.
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Arizona
Phoenix, Arizona, United States
Local Institution - 0020
Duarte, California, United States
University Of Colorado
Aurora, Colorado, United States
Local Institution - 0032
New Haven, Connecticut, United States
Local Institution - 0036
Washington D.C., District of Columbia, United States
UF Health Medical Oncology - Davis Cancer Pavilion
Gainesville, Florida, United States
Local Institution - 0038
Jacksonville, Florida, United States
Local Institution - 0006
Baltimore, Maryland, United States
Local Institution - 0017
Rochester, Minnesota, United States
Local Institution - 0003
St Louis, Missouri, United States
Local Institution - 0001
Hackensack, New Jersey, United States
Local Institution - 0007
New York, New York, United States
Local Institution - 0002
Portland, Oregon, United States
Local Institution - 0005
Philadelphia, Pennsylvania, United States
UPMC
Pittsburgh, Pennsylvania, United States
Local Institution - 0004
Seattle, Washington, United States
Local Institution - 0035
Westmead, New South Wales, Australia
Local Institution - 0033
Heidelberg, Victoria, Australia
Local Institution
Randwick, , Australia
Local Institution
Edmonton, Alberta, Canada
Local Institution
Vancouver, British Columbia, Canada
Local Institution
Ottawa, Ontario, Canada
Local Institution - 0025
Toronto, Ontario, Canada
Local Institution - 0021
Toronto, Ontario, Canada
Local Institution - 0039
Heidelberg, , Germany
Local Institution - 0043
Leipzig, , Germany
Local Institution
Ramat Gan, , Israel
Local Institution
Tel Aviv, , Israel
Local Institution - 0014
Milan, Lombardy, Italy
IRCCS Istituto Nazionale Tumori Milano
Milan, , Italy
Local Institution
Amsterdam, , Netherlands
Local Institution
Utrecht, , Netherlands
Local Institution - 0050
Singapore, , Singapore
Local Institution - 0041
Chur, Graubünden (de), Switzerland
Local Institution - 0042
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Investigator Inquiry Form
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-002807-24
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CA018-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.